A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
Authors
Maung, Su WLeahy, Maeve
O'Leary, Hilary M
Khan, Irfan
Cahill, Mary R
Gilligan, Oonagh
Murphy, Philip
McPherson, Suzanne
Jackson, Fred
Ryan, Mary
Hennessy, Brian
McHugh, Johnny
Goodyer, Matthew
Bacon, Larry
O'Gorman, Peter
Nee, Aisling
O'Dwyer, Michael
Enright, Helen
Saunders, Jean
O'Keeffe, Denis
Affiliation
Department of Haematology, University Hospital Limerick, Limerick, Ireland; Department of Haematology, Tallaght Hospital (AMNCH), Dublin, Ireland.Issue Date
2013-10MeSH
AdolescentAdult
Aged
Aged, 80 and over
Anemia, Hemolytic, Autoimmune
Antibodies, Monoclonal, Murine-Derived
Female
Humans
Immunologic Factors
Ireland
Male
Middle Aged
Recurrence
Retrospective Studies
Treatment Outcome
Young Adult
Metadata
Show full item recordCitation
A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. 2013, 163 (1):118-22 Br. J. Haematol.Journal
British journal of haematologyDOI
10.1111/bjh.12486PubMed ID
23909468Additional Links
http://onlinelibrary.wiley.com/doi/10.1111/bjh.12486/abstractAbstract
This retrospective analysis assessed the response, safety and duration of response to standard dose rituximab 375 mg/m(2) weekly for four weeks as therapy for patients with primary or secondary warm autoimmune haemolytic anaemia (WAIHA), who had failed initial treatment. Thirty-four patients received rituximab for WAIHA in seven centres in the Republic of Ireland. The overall response rate was 70·6% (24/34) with 26·5% (9/34) achieving a complete response (CR). The time to response was 1 month post-initiation of rituximab in 87·5% (21/24) and 3 months in 12·5% (3/24) of patients. The median duration of follow-up was 36 months (range 6-90 months). Of the patients who responded, 50% (12/24) relapsed during follow up with a median time to next treatment of 16·5 months (range 6-60 months). Three patients were re-treated with rituximab 375 mg/m2 weekly for four weeks at relapse and responded. There was a single episode of neutropenic sepsis. Rituximab is an effective and safe treatment for WAIHA but a significant number of patients will relapse in the first two years post treatment. Re-treatment was effective in a small number of patients, suggesting that intermittent pulse treatment or maintenance treatment may improve long-term response.Item Type
ArticleLanguage
enISSN
1365-2141ae974a485f413a2113503eed53cd6c53
10.1111/bjh.12486
Scopus Count
Collections
Related articles
- Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases.
- Authors: Bussone G, Ribeiro E, Dechartres A, Viallard JF, Bonnotte B, Fain O, Godeau B, Michel M
- Issue date: 2009 Mar
- Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
- Authors: Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R
- Issue date: 2012 Sep
- A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
- Authors: Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Rønnov-Jessen D, Vestergaard H, Klausen TW, Schöllkopf C
- Issue date: 2013 Nov
- Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
- Authors: Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A
- Issue date: 2009 Nov
- Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia.
- Authors: Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Di Bona E, Fattizzo B, Consonni D, Cortelezzi A, Zanella A
- Issue date: 2013 Dec